title: Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy.
abstract: BACKGROUND
  A negative sentinel node biopsy (SNB) implies a good prognosis for melanoma patients. The purpose of this study was to determine the long-term outcome for melanoma patients with a negative SNB.
  
  
  METHODS
  Survival and prognostic factors were analyzed for 836 SNB-negative patients. All patients with a node field recurrence were reviewed, and sentinel node (SN) tissue was reexamined.
  
  
  RESULTS
  The median tumor thickness was 1.7 mm, and 23.8% were ulcerated. The median follow-up was 42.1 months. Melanoma specific survival at 5 years was 90%, compared with 56% for SN-positive patients (P < .001). On multivariate analysis, only thickness and ulceration retained significance for disease-free and disease-specific survival. Five-year survival for patients with nonulcerated lesions was 94% vs. 78% with ulceration. Eighty-three patients (9.9%) had a recurrence. Twenty-seven patients developed recurrence in the regional node field, and in 22 of these, it was the first recurrence site. Six developed local recurrence, 17 an in-transit metastasis, and 58 distant disease. The false-negative rate was 13.2%. SN slides and tissue blocks were further examined in 18 patients with recurrence in the node field, and metastatic disease was found in 3 of them.
  
  
  CONCLUSIONS
  This large, single-center study confirms that patients with a negative SNB have a significantly better prognosis than those with positive SNs. In those with a negative SNB, primary tumor thickness and ulceration are independent predictors of survival. Incorrect pathologic diagnosis contributed to only a minority of the false-negative results in this study.
authors.affiliation: Sydney Melanoma Unit, Sydney Cancer Centre, Gloucester House, Royal Prince Alfred Hospital, Missenden Road, Camperdown, 2050 New South Wales, Australia.
authors.forename: Vivian S K
authors.initials: VS
authors.lastname: Yee
authors.forename: John F
authors.initials: JF
authors.lastname: Thompson
authors.forename: J Gregory
authors.initials: JG
authors.lastname: McKinnon
authors.forename: Richard A
authors.initials: RA
authors.lastname: Scolyer
authors.forename: Ling-Xi L
authors.initials: LX
authors.lastname: Li
authors.forename: William H
authors.initials: WH
authors.lastname: McCarthy
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: O'Brien
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Quinn
authors.forename: Robyn P M
authors.initials: RP
authors.lastname: Saw
authors.forename: Kerwin F
authors.initials: KF
authors.lastname: Shannon
authors.forename: Jonathan R
authors.initials: JR
authors.lastname: Stretch
authors.forename: Roger F
authors.initials: RF
authors.lastname: Uren
mesh_terms: D005188:False Negative Reactions; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008545:Melanoma / Q000473:pathology*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D021701:Sentinel Lymph Node Biopsy; D012878:Skin Neoplasms / Q000473:pathology*; D016019:Survival Analysis